Chargement en cours...
Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study
OBJECTIVES: Crizotinib has demonstrated good efficacy in patients with anaplastic lymphoma kinase (ALK)‐positive non‐small cell lung cancer (NSCLC). Continuing crizotinib therapy beyond progressive disease (CBPD) can achieve ongoing survival benefit in real‐world clinical practice. In terms of survi...
Enregistré dans:
| Publié dans: | Cancer Med |
|---|---|
| Auteurs principaux: | , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley and Sons Inc.
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6792485/ https://ncbi.nlm.nih.gov/pubmed/31407528 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2420 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|